These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

922 related items for PubMed ID: 15145150

  • 1. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T, Kitamoto Y, Saito J, Harashima K, Nakano T, Ito K, Yamamoto T, Kurokawa K, Yamanaka H, Takahashi M, Mitsuhashi N, Niibe H.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):372-9. PubMed ID: 15145150
    [Abstract] [Full Text] [Related]

  • 2. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
    Ogawa K, Nakamura K, Sasaki T, Onishi H, Koizumi M, Shioyama Y, Araya M, Mukumoto N, Mitsumori M, Teshima T, Japanese Patterns of Care Study Working Subgroup of Prostate Cancer.
    Int J Radiat Oncol Biol Phys; 2009 Jul 01; 74(3):759-65. PubMed ID: 19327908
    [Abstract] [Full Text] [Related]

  • 3. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 4. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 5. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1140-50. PubMed ID: 16198506
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1322-31. PubMed ID: 16029788
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):15-23. PubMed ID: 15337535
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
    Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES.
    J Clin Oncol; 2005 Feb 01; 23(4):826-31. PubMed ID: 15681527
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
    Ludgate CM, Bishop DC, Pai H, Eldridge B, Lim J, Berthelet E, Blood P, Piercy GB, Steinhoff G.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1309-15. PubMed ID: 16029786
    [Abstract] [Full Text] [Related]

  • 17. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
    Zagars GK, Pollack A, von Eschenbach AC.
    Cancer; 1997 Apr 01; 79(7):1370-80. PubMed ID: 9083160
    [Abstract] [Full Text] [Related]

  • 18. Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.
    Tomioka S, Shimbo M, Amiya Y, Nakatsu H, Murakami S, Shimazaki J.
    Int J Urol; 2007 Feb 01; 14(2):123-7. PubMed ID: 17302568
    [Abstract] [Full Text] [Related]

  • 19. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1003-10. PubMed ID: 15752879
    [Abstract] [Full Text] [Related]

  • 20. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):32-43. PubMed ID: 15629591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.